Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...

Vivani Medical (VANI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

Jane Street Group LLC purchased a new stake in Vivani Medical in the 4th quarter valued at $66,000. Wealthedge Investment Advisors LLC acquired a new stake in Vivani Medical in the 4th quarter ...

HC Wainwright reduced their FY2024 earnings estimates for shares of Vivani Medical in a note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company ...

Short interest in Vivani Medical Inc (NASDAQ:VANI) decreased during the last reporting period, falling from 300.99K to 279.35K. This put 0.82% of the company's publicly available shares short.